Loading publications…
The last 5 uploaded publications
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
Kim N., Dana E. Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J. Small, Andrea Juliana Gomes, Guilhem Roubaud, Marniza Saad, Bogdan Żurawski, V.S. Sakalo, Gary Mason, Peter Francis, George Wang, Daphne Wu, Brooke Diorio, Angela Lopez‐Gitlitz, Shahneen Sandhu (2025). A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer. , DOI: https://doi.org/10.1080/14796694.2025.2470106.
Article62 days agoFinal Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial
Johann S. de Bono, He Meng, Zhen Shi, Małgorzata Nowicka, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Geng Chen, Nives Selak Bienz, Daniel Canter, Matthew Wongchenko, Christopher J. Sweeney (2025). Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. , DOI: https://doi.org/10.1016/j.eururo.2024.12.015.
Article62 days agoNiraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial
Kim N., Elena Castro, G. Attard, Matthew R. Smith, Shahneen Sandhu, Eleni Efstathiou, Guilhem Roubaud, Eric J. Small, A Gomes, Dana E. Rathkopf, Marniza Saad, Howard Gurney, Wonho Jung, Won Kim, Shiva Dibaj, Daphne Wu, Jenny Zhang, Angela Lopez‐Gitlitz, Peter Francis, David Olmos (2025). Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial. , DOI: https://doi.org/10.1016/j.euo.2025.04.012.
Article62 days agoSupplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Joaquı́n Mateo, David Olmos, Niven Mehra, Michael Paul Kolinsky, Guilhem Roubaud, Mustafa Özgüroğlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman, Allison Allen, Christian Poehlein, Johann S. de Bono (2023). Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). , DOI: https://doi.org/10.1158/1078-0432.22486373.
Preprint62 days agoPhase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.
Gerhardt Attard, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Eleni Efstathiou, Mustafa Özgüroğlu, Andrea Juliana Gomes, Karina Costa Maia Vianna, Hong Luo, Heather H. Cheng, Won Bae Kim, Carlos Federico Varela, Daneen Schaeffer, Shiva Dibaj, Susan Li, Fei Shen, Suneel Mundle, David Olmos, Kim N., Dana E. Rathkopf (2025). Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.. , 43(17_suppl), DOI: https://doi.org/10.1200/jco.2025.43.17_suppl.lba5006.
Article62 days ago